Mechanisms for hyperglycemia in the metabolic syndrome. The key role of β-cell dysfunction

Annals of the New York Academy of Sciences

Volumn 892, Issue , 1999, Pages 73-83

  Porte Jr , Daniel ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ATHEROSCLEROSIS; CELL FUNCTION; CONFERENCE PAPER; DYSLIPIDEMIA; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL;

EID: 0032786471     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07786.x     Document Type: Conference Paper

References (27)

1. 1. Kahn, S. E. & D. Porte, Jr. 1997. The pathophysiology of type II (noninsulin dependent) diabetes mellitus: implications for treatment. In Diabetes Mellitus. D. Porte, Jr. & R. S. Sherwin, Eds.: 487-512. Appleton & Lange. Stamford, CT.
2. 2. Harris, M. I., R. C. Eastman, C. C. Cowie, K. M. Flegal & M. S. Eberhardt. 1997. Comparison of diabetes diagnostic categories in the U.S. population according to 1997 American Diabetes Association and 1980-1985 World Health Organization Diagnostic Criteria. Diabetes Care 20: 1859-1862.
3. 3. Harris, M. I., K. M. Flegal, C. C. Cowie, M. S. Eberhardt, et al. 1998. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 21: 518-524.
4. 4. Edelstein, S. L., W. C. Knowler, R. P. Bain, R. Andres, et al. 1997. Predictors of progression from impaired glucose tolerance to NIDDM. Diabetes 46: 701-710.
5. 5. Porte, D., Jr. & S. E. Kahn. 1999. Pathophysiology of impaired glucose tolerance. Curr. Opin. Endocrinol. Diabetes. In press.
6. 6. Porte, D., Jr. & S. E. Kahn. 1995. The key role of islet dysfunction in type 2 diabetes mellitus. Clin. Invest. Med. 18: 247-254.
7. 7. Kahn, S. E., R. L. Prigeon, D. K. McCulloch, E. J. Boyko, et al. 1993. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Diabetes 42: 1663-1672.
8. 8. Bergman, R. N., L. S. Phillips & C. Cobelli. 1981. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J. Clin. Invest. 68: 1456-1467.
9. 9. Beard, J. C., R. N. Bergman, W. K. Ward & D. Porte, Jr. 1986. The insulin sensitivity index in man: correlation between clamp-derived and IVGTT-derived values. Diabetes 35: 362-369.
10. 10. Porte, D., Jr. 1996. Normal physiology and phenotypic characterization of beta cell function in subjects at risk for type 2 diabetes mellitus. Diabetic Med. 13: S25-S32.
11. 11. Howell, W. M., R. L. Prigeon, W. Y. Fujimoto, S. E. Kahn & The GENNID Study Group. 1998. Comparison of estimates of insulin sensitivity and B-cell function derived from oral glucose tolerance test versus the intravenous glucose tolerance test and minimal model. Diabetes 47: A179.
12. 12. Mitrakou, A., D. Kelley, M. Mokan, T. Veneman, et al. 1992. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl. J. Med. 326: 22-29.
13. 13. Vaag, A., J. Henriksen, S. Madsbad, N. Holm & H. Beck-Nielsen. 1995. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J. Clin. Invest. 95: 690-698.
14. 14. Araki, E., M. A. Lipes, M. E. Patti, J. C. Bruning, et al. 1994. Alternative pathway of insulin signaling in mice with targeted disruption of the IRS-1 gene. Nature 372: 186-190.
15. 15. Tamemoto, H., T. Kadowaki, K. Tobe, T. Yagi, et al. 1994. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372: 182-186.
16. 16. Bruning, J. D., J. Winnay, S. Bonner-Weir, S. I. Taylor, et al. 1997. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 88: 561-572.
17. 17. Terauchi, Y., H. Sakura, K. Yasuda, K. Iwamoto, et al. 1995. Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J. Biol. Chem. 270: 30253-30256.
18. 18. Fujimoto, W. Y., S. L. Abbate, S. E. Kahn, J. E. Hokanson & J. D. Brunzell. 1994. The visceral adiposity syndrome in Japanese-American men. Obes. Res. 2: 364-371.
19. 19. Fujimoto, W. Y., R. W. Bergstrom, E. J. Boyko, J. L. Kimyoun, et al. 1994. Diabetes and diabetes risk factors in second- and third-generation Japanese-Americans in Seattle, Washington. Diabetes Res. Clin. Pract. 24: S43-S52.
20. 20. Stone, L. M., S. E. Kahn, W. Y. Fujimoto, S. S. Deeb & D. Porte, Jr. 1996. A variation at position -30 of the B-cell GK gene promoter is associated with reduced B-cell function. Diabetes 45: 422-428.
21. 21. Chen, K. W., E. J. Boyko, R. W. Bergstrom, D. L. Leonetti, et al. 1995. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. Diabetes Care 18: 747-753.
22. 22. Porte, D., Jr., R. J. Seeley, S. C. Woods, D. G. Baskin, et al. 1998. Obesity, diabetes and the central nervous system. Diabetologia 41: 863-881.
23. 23. Schwartz, M. W., E. J. Boyko, S. E. Kahn, E. Ravussin & C. Bogardus. 1995. Reduced insulin secretion: an independent predictor of body weight gain. J. Clin. Endocrinol. Metab. 80: 1571-1576.
24. 24. Swinburn, B. A., B. L. Nyomba, M. F. Saad, F. Zurlo, et al. 1991. Insulin resistance associated with lower rates of weight gain in Pima Indians. J. Clin. Invest. 88: 168-173.
25. 25. Kahn, S. E., D. L. Leonetti, R. L. Prigeon, E. J. Boyko, et al. 1995. Relationship of proinsulin and insulin with non-insulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity - clinical research center study. J. Clin. Endocrinol. Metab. 80: 1399-1406.
26. 26. Porte, D., Jr. & S. E. Kahn. 1989. Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β-cell dysfunction? Diabetes 38: 1333-1336.
27. 27. Kahn, S. E., S. Andrikopoulos & C. B. Verchere. 1999. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48: 241-253.